Mediolanum International Funds Ltd Acquires 157 Shares of Zoetis Inc. (NYSE:ZTS)

Mediolanum International Funds Ltd increased its holdings in Zoetis Inc. (NYSE:ZTS) by 0.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 199,586 shares of the company’s stock after purchasing an additional 157 shares during the period. Mediolanum International Funds Ltd’s holdings in Zoetis were worth $32,301,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ZTS. Algert Global LLC increased its position in Zoetis by 29.5% during the second quarter. Algert Global LLC now owns 1,924 shares of the company’s stock valued at $334,000 after acquiring an additional 438 shares during the last quarter. Quarry LP increased its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. Truist Financial Corp increased its position in Zoetis by 1.5% during the second quarter. Truist Financial Corp now owns 169,202 shares of the company’s stock valued at $29,333,000 after acquiring an additional 2,557 shares during the last quarter. Sanctuary Advisors LLC bought a new position in Zoetis during the second quarter valued at $19,525,000. Finally, Heritage Wealth Management Inc. bought a new position in Zoetis during the second quarter valued at $624,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $172.61 on Friday. The firm has a market capitalization of $77.88 billion, a P/E ratio of 32.45, a PEG ratio of 2.70 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a 50 day moving average price of $169.82 and a 200 day moving average price of $179.59. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $1.36 EPS. Sell-side analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ZTS shares. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Morgan Stanley cut their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.